Gilead Sciences (NASDAQ: GILD) said on 19 October 2026 that its experimental oral ulcerative colitis pill, emvistegrast, met the main goal of the mid-stage SWIFT trial. At the 200mg dose, 66% of patients reached clinical response at Week 12 versus 37% on placebo, and 31% achieved clinical remission versus 8% on placebo. Despite the positive readout, GILD shares closed at $153.555, down 1.42%, on volume of 0.82 times the 20-day average, and RBC Capital Markets had said the data were unlikely to move the stock. The results follow a volatile quarter: Gilead posted a Q2 2026 net loss of $10,496m (EPS -$8.45) versus net income of $2,021m in Q1, though Q2 revenue rose to $7,803m from $6,960m. Gilead has not disclosed a timeline for advancing emvistegrast into late-stage testing.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on financial-news.co.uk ↗
Keywords
Open a keyword to see other news on the same topic.
Related news
- Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share
Regeneron has lagged broader equities over the past two years mainly because Eylea sales are falling under biosimilar and other competition, although the newer high-dose version is performing well. In the second quarter, revenue rose 17% to $4.3 billion, global Dupixent sales reached $6 billion, up 38%, and collaboration revenue from Sanofi grew 51% to $2.2 billion. Non-GAAP earnings per share rose 11% to $14.29, but combined U.S. Eylea revenue fell 12% to about $1 billion. The author believes Regeneron can navigate the possible biosimilar threat to Dupixent in the early 2030s through a new formulation, replacement medicines in development and its own pipeline, including the weight-loss candidate olatorepatide, and expects competitive returns over the medium term.
- Should You Invest in This Dividend King on the Dip?
Johnson & Johnson (JNJ) shares fell significantly after its third-quarter results, even though the company beat expectations and slightly raised its full-year guidance. Revenue reached $25.4 billion, up 5.9%, while adjusted EPS of $2.59 fell 7.5%, a decline the company attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by Darzalex and Tremfya, but medtech revenue of $8.6 billion, up 2.5%, fell short of expectations and drove the post-earnings dip, with the cardiovascular unit hurt by safety and efficacy concerns about the Impella heart pumps. The article points to new drugs such as ICOTYDE and Imaavy as medium-term growth drivers and says the Ottava robotic surgery device could help medtech recover. The author argues investors should hold the stock for the long term, citing JNJ's 64 consecutive years of dividend increases.
- These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Eli Lilly Leads Industry
- Palo Alto Falls 4% as Report of OpenAI Cybersecurity Deal Hits Sector; CrowdStrike Drops 3%, Fortinet Slips
A report that OpenAI plans to buy a cybersecurity startup pushed down shares of the sector's largest names. Palo Alto Networks (PANW) fell 4% to $381.88, though it is still up 105% this year; CrowdStrike (CRWD) dropped 3% to $254.05, Fortinet (FTNT) slipped 1% to $188.66, the CIBR ETF fell 1.4% and QQQ fell 1%. No terms or target company have been disclosed, so the size of any deal is unknown. Palo Alto recently signed a $126 million agreement with a global telecom customer to expand its next-generation firewalls, and CEO Nikesh Arora said OpenAI, Anthropic and Google had approached it about partnerships, adding that customers' push to standardize on one platform favors larger vendors. The open question is whether OpenAI would sell through incumbents or compete directly for their customers.
Related markets
Latest news
- Meta Earnings: What To Look For From META
Meta Platforms (NASDAQ:META) will report earnings this Wednesday after the market closes. Last quarter, revenue reached $60.8 billion, up 28% year on year and above analysts' expectations, though revenue guidance for next quarter slightly missed forecasts; daily active users hit 3.6 billion, up 3.4%. The market expects revenue growth of 23.6% this quarter, slowing from 26.2% a year earlier, and analysts have generally reconfirmed their estimates over the past 30 days. Over the last month, consumer internet stocks have gained 1.3% on average, while Meta is down 4.8%.
- An AI bust could come from places investors arent watching , an economist says
Concerns about an AI bubble are growing, and TS Lombard's Dario Perkins warns that investors may be overlooking other risks. Debt among smaller cloud providers, model developers and suppliers could reach $2 trillion by the end of 2027. Perkins does not see this as a systemic risk, but warns that earnings disappointments and canceled orders could ripple through the ecosystem, and that a chip glut could follow over-ordering. Much of the industry's revenue growth still comes from spending within the AI ecosystem rather than from businesses and consumers outside it. He also flags political backlash, noting that ordinary people dislike AI and nearby datacenters, and warns that one high-profile accident could turn AI toxic.
- Yen jumps after JGB auction draws big demand , euro finds relief
The yen rose 0.2% to 158.15 per dollar in Asian trading after a 20-year Japanese government bond auction drew bids of 5.84 times the amount sold, well above the 4.01 times at the previous auction, and the yield fell 6 basis points to 3.71%. A State Street strategist said the record demand suggests sidelined cash is returning and that JGBs are becoming a relative haven from political and fiscal volatility in Europe, particularly France. Anti-government protests in France prompted curfews in several cities, while Italy said it would send 500 troops after two days of unrest, and the euro rallied 0.2% to $1.1234. Elsewhere, bitcoin slipped 0.3% to $81,674.25 and ether edged down 0.2% to $2,393.21.
- Unemployment rate dips to 4 . 7 % - but vacancies hit five - year low
Vacancies fell by 21,000 to 691,000 in the three months to September, the biggest drop since the three months to March and the lowest since July to September 2014 outside the pandemic, while unemployment dipped in the three months to August. Payroll numbers were down 66,000 over the year to September. The ONS said the fall was mainly among smaller firms struggling with higher labour costs, following rises in employer national insurance, the minimum wage and workers' rights. A CBI survey found labour costs and regulations were making it harder to create jobs, and firms urged the Chancellor not to add to their burden in the October 28 Budget. ICAEW's Suren Thiru said the labour market is 'running on idle' and unemployment could climb above 5 per cent, while Shadow Chancellor Andrew Griffith blamed Labour's 'Jobs Tax' and red tape.
- CNBC Daily Open: Tech rebounds in the U.S., but Asia isn’t buying it yet
U.S. tech stocks rebounded as the Nasdaq Composite rose more than 1% on Monday, with Nvidia up 1.4% and Tesla up 3.8%. In Asia, however, tech shares fell on Tuesday, with South Korea's Kospi down over 4% and Japan's Nikkei 225 down 1.6%. Nvidia also unveiled plans to back four German AI startups as part of its nearly $10 billion European investment commitment. Jenny Lee of Granite Asia said Asian companies are reaching IPOs much sooner, often at four to five years old, while Jio Platforms' Indian IPO saw its anchor investor quota oversubscribed more than 30 times, aiming to raise up to 302 billion rupees ($3.2 billion). In Singapore, several agricultural stocks fell after Senior Minister K Shanmugam warned that companies would not escape responsibility for possible roles in the haze, noting seven firms had been questioned by the Singapore Exchange.
- NiSource (NI) Stock Looks Overvalued Against Its Dividend Outlook
NiSource has nearly doubled shareholders' money over the past five years, delivering a 97.6% total return, which raises the question of whether dividends can justify the current share price. The article highlights a new 20-year energy agreement with Microsoft, including customer-funded grid upgrades and long-term electric service for data centers, which may affect future capital needs and cash-flow visibility. Using a Dividend Discount Model with inputs of about $1.35 dividend per share, roughly 9.07% return on equity, a payout ratio slightly above 61%, and implied dividend growth of about 3.5%, the estimated intrinsic value sits meaningfully below the current share price of $41.95. The model still does not bridge that gap, suggesting income investors are paying a premium for a relatively steady payout with modest assumed growth.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.